Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels

The placebo-controlled, double blind parallel intervention trial "PostWelLB" aims to test whether 3 months of daily supplementation with the postbiotic product "Humiome® Post LB" (HPLB; 340 mg / day) can reduce self-reported stress (PSS10 questionnaire)- in an older (50 - 75 years; all genders) population in France.

NCT Number	NCT07471659
Lead Sponsor	dsm-firmenich Switzerland AG Collaborators: BioFortis
Conditions	Stress
Enrollment	200 participants
Start Date	2026-04
Primary Completion	2026-11 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-23